Visualisation of bladder cancer using 11C-choline PET: First clinical experience

European Journal of Nuclear Medicine

Volumn 29, Issue 10, 2002, Pages 1283-1288

  De Jong, Igle J ^a   Pruim, Jan ^a   Elsinga, Philip H ^a   Jongen, Maud M ^a   Mensink, Han J ^a   Vaalburg, Willem ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Bladder cancer; Choline; Positron emission tomography

Indexed keywords

CARBON 11; CHOLINE DERIVATIVE; FLUORODEOXYGLUCOSE F 18; GOLD; RADIOPHARMACEUTICAL AGENT; CHOLINE; CARBON; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; BLADDER WALL; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTECTOMY; DYSPLASIA; HISTOPATHOLOGY; HUMAN; INDWELLING CATHETER; LYMPH NODE METASTASIS; POSITRON EMISSION TOMOGRAPHY; PROSTATE; RADIOACTIVITY; RECTUM; SMALL INTESTINE; TRANSURETHRAL RESECTION; URINARY EXCRETION; URINARY TRACT; UROGENITAL TRACT TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GOLD STANDARD; HUMAN TISSUE; MICROMETASTASIS; TUMOR BIOPSY; BLADDER TUMOR; CARCINOSARCOMA; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; LABORATORY DIAGNOSIS; METHODOLOGY; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; NEOPLASM; PATHOLOGY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARBON RADIOISOTOPES; CARCINOMA, SQUAMOUS CELL; CARCINOSARCOMA; CHOLINE; CYSTECTOMY; FALSE POSITIVE REACTIONS; HUMANS; MIDDLE AGED; NEOPLASM, RESIDUAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; URINARY BLADDER NEOPLASMS;

EID: 0036383491     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-0881-7     Document Type: Article

References (24)

1. Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III". Eur J Nucl Med 2001; 28:1707-1723.
2. 18F]-2-deoxy-D-glucose. Eur Urol 1999; 36: 582-587.
3. Bachor R, Kotzerke J, Reske SN, Hautmann R. Lymph node staging of bladder neck carcinoma with positron emission tomography. Urologe A 1999; 38:46-50.
4. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998; 39:990-995.
5. Hara T, Kosada N, Kondo T, Kishi H, Kobori O. Imaging of brain tumor, lung cancer, esophageal cancer, colon cancer, prostate cancer and bladder cancer with (C-11)choline [abstract]. J Nucl Med 1997; 38:250P.
6. Zeisel SH. Dietary choline: biochemistry, physiology and pharmacology. Annu Rev Nutr 1981; 1:95-121.
7. Podo F. Tumor phospholipid metabolism. NMR Biomed 1999; 12:413-439.
8. Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlman A, Kleinschmidt K, Hautmann R, Reske SN. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000; 27:1415-1419.
9. 18F]fluoroethyl-dimethyl-2-oxyethylammonium (choline analog): automated synthesis and tumor imaging. J Labelled Compd Radiopharm 1997; 40:670.
10. Kosuda S, Kison PV, Greenough R, Grossman HB, Wahl RL. Preliminary assesment of fluorine-18 fluorodeoxyglucose tomography in patients with bladder cancer. Eur J Nucl Med 1997; 24:615-620.
11. Hofer C, Laubenbacher C, Hofer C, Breul J, Hartung R, Schwaiger M. Fluorine-18 fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999; 36:31-35.
12. Hoh CK, Seltzer MA, Franklin J, deKernion JB, Phelps ME, Belldegrun A. Positron emission tomography in urological oncology. J Urol 1998; 159:347-356.
13. Alhstrom H, Malmstrom PU, Letocha H, Andersson J, Lanhstrom B, Nilsson S. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol 1996; 2:180-185.
14. 11C-methionine in the monitoring of therapy response in muscle invasive transitional cell carcinoma of the urinary bladder. Br J Urol 1994; 74:767-774.
15. Katz-Brull R, Degani H. Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res 1996; 16: 1375-1380.
16. Heerschap A, Jager GJ, van der Graaf M, Barentsz JO, de la Rosette JJ, Oosterhof GO, Ruijter ET, Ruijs SH. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. Anticancer Res 1997; 17:1455-1460.
17. Zeisel SH. Choline phosphoplipids; signal transduction and carcinogenesis. FASEB J 1993; 7:551-557.
18. Shinoura N, Nishijima M, Hara T, Haisa T, Yamamoto H, Fuji K, Mitsui I, Kosaka N, Kondo T, Hara T. Brain tumors: detection with C-11 choline PET. Radiology 1997; 202:497-503.
19. Jager, PL, Que TH, Vaalburg W, Pruim J, Elsinga P, Plukker JT. Carbon-11 choline or FDG-PET for staging of oesophageal cancer? Eur J Nucl Med 2001; 12:1845-1849.
20. Isidate K. Choline transport and choline kinase. In: Vance DE, ed. Phosphatidylcholine metabolism. Boca Raton, Fl.: CRC Press; 1989:9-32.
21. 11C]choline; implications for in vivo imaging with positron emission tomography. Eur J Nucl Med 2000; 27:25-32.
22. Lewis PJ, Salama A. Uptake of fluorine-18 fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35:1647-1649.
23. 18F]-fluodeoxyglucose uptake in abdominal abscesses: a PET study. J Comput Assist Tomogr 1989; 13:829-831.
24. 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001; 61:110-117.